The purpose of the Administrative Core is to establish the research agenda for the ADRC and to insure the optimal utilization of Center resources by maximizing institutional strengths in the service of broadening knowledge about diagnosis, management, treatment, and prevention of AD and other dementias through basic and applied research.
The specific aims are to 1) Provide the leadership to facilitate the overall research goals of the ADRC. 2) Coordinate and integrate ADRC activities ensuring that the Cores meet the needs of the Projects and that the Projects are utilizing the Cores. 3)Foster growth of new research initiatives and recruit new researchers through the pilot program and through other institutional resources. 4) Ensure future growth for the ADRC. This includes maintaining a proper balance of faculty and staff renewal in order to insure that our clinical and other core operations are accomplished and also setting future directions and optimizing resources available to Insure that our research efforts grow. 5) Facilitate communication: (a) with NACC to insure timely transmission of data sets;(b) with other ADCs to maximize collaboration;and (c) with NIA program staff including coordination with NIA on media coverage and dissemination of Important findings. 6) Facilitate interaction with the Alzheimer's Disease Cooperative Study and other clinical trial organizations. 7) Provide administrative oversight. This includes developing and maintaining budgets and ensuring that funds are utilized to conduct and enhance Core and scientific activities. The Core functions are managed through routine meetings and reporting and auditing routines. The leadership of the Core is advised by both internal and external advisory boards.
The Administration Core functions to insure commitment to cutting edge science that will lead to early diagnosis, better treatments, and, ultimately, prevention of Alzheimer's disease and other cognitive disorders.
|Amrock, Levana G; Deiner, Stacie (2014) The implication of frailty on preoperative risk assessment. Curr Opin Anaesthesiol 27:330-5|
|Mitsis, Effie M; Bender, Heidi A; Kostakoglu, Lale et al. (2014) A consecutive case series experience with [18?F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener 9:10|
|Lunnon, Katie; Smith, Rebecca; Hannon, Eilis et al. (2014) Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci 17:1164-70|
|Dekosky, Steven T; Gandy, Sam (2014) Environmental exposures and the risk for Alzheimer disease: can we identify the smoking guns? JAMA Neurol 71:273-5|
|Roussos, Panos; Mitchell, Amanda C; Voloudakis, Georgios et al. (2014) A role for noncoding variation in schizophrenia. Cell Rep 9:1417-29|
|Ravona-Springer, Ramit; Heymann, Anthony; Schmeidler, James et al. (2014) The ApoE4 genotype modifies the relationship of long-term glycemic control with cognitive functioning in elderly with type 2 diabetes. Eur Neuropsychopharmacol 24:1303-8|
|Jun, Gyungah; Asai, Hirohide; Zeldich, Ella et al. (2014) PLXNA4 is associated with Alzheimer disease and modulates tau phosphorylation. Ann Neurol 76:379-92|
|Neugroschl, Judith; Sano, Mary; Luo, Xiaodong et al. (2014) Why They Stay: Understanding Research Participant Retention in Studies of Aging, Cognitive Impairment and Dementia. J Gerontol Geriatr Res 3:|
|Babi?, Mirjana; Svob Štrac, Dubravka; Mück-Šeler, Dorotea et al. (2014) Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. Croat Med J 55:347-65|
|Greenbaum, Lior; Springer, Ramit Ravona; Lutz, Michael W et al. (2014) The TOMM40 poly-T rs10524523 variant is associated with cognitive performance among non-demented elderly with type 2 diabetes. Eur Neuropsychopharmacol 24:1492-9|
Showing the most recent 10 out of 255 publications